CeQur Closes $100 Million Series E Financing to Expand Mealtime Insulin Delivery Solution

CeQur, the Switzerland-based company dedicated to simplifying mealtime insulin delivery for people living with diabetes, has announced the close of a $100 million Series E financing round to accelerate growth across every dimension of its commercial operation and expand the field sales team.

With new FDA clearances, compelling clinical data, and $100 million in capital, CeQur Simplicity is well-positioned to provide patients with a simpler approach to insulin delivery. CeQur Simplicity is steadily gaining adoption across primary care and endocrinology practices nationwide. More than 85 percent of claims are covered as a pharmacy benefit, with an average copay of less than $45 per month. Nearly 90 percent of patients reported better adherence to their insulin regimen with CeQur Simplicity compared to multiple daily injections, resulting in significantly improved A1C and time-in-range outcomes.

The investment reflects sustained investor confidence in CeQur’s commercial trajectory, its pipeline, and growing demand for a simpler approach to mealtime insulin. The Series E marks the beginning of the company’s most ambitious phase of commercial growth. Bradley Paddock, President and Chief Executive Officer of CeQur, stated that the company has the commercial infrastructure, new clinical evidence, and an exciting pipeline, and now has the capital to accelerate its growth, making CeQur Simplicity ready to reach every patient.